Crossmark

Recent progress and challenges in screening and characterization of UGT1A1 inhibitors

Crossref DOI link: https://doi.org/10.1016/j.apsb.2018.09.005

Published Print: 2019-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Lv, Xia

Xia, Yangliu

Finel, Moshe

Wu, Jingjing

Ge, Guangbo

Yang, Ling
Funding

Funding for this research was provided by:

National Key Research and Development Program of China (2017YFC1700200)

National Key Research and Development Program of China (2017YFC1702000)

Fundamental Research Funds for the Central Universities (wd01185)

National S&T Major Projects of China (2017ZX09101004)

Program of Shanghai Academic/Technology Research Leader (18XD1403600)

Innovative Entrepreneurship Program of High-level Talents in Dalian (2016RQ025)

Innovative Entrepreneurship Program of High-level Talents in Dalian (2017RQ121)

Doctoral Scientific Research Foundation of Liaoning Province (20170520059)
License Information

Text and Data Mining valid from 2019-03-01

Text and Data Mining valid from 2019-03-01

Version of Record valid from 2018-09-11
More Information

This article is maintained by: Elsevier

Article Title: Recent progress and challenges in screening and characterization of UGT1A1 inhibitors

Journal Title: Acta Pharmaceutica Sinica B

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.apsb.2018.09.005

Content Type: article

Copyright: © 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.